Progress in the identification of dengue virus entry/fusion inhibitors.
Dengue fever, a reemerging disease, is putting nearly 2.5 billion people at risk worldwide. The number of infections and the geographic extension of dengue fever infection have increased in the past decade. The disease is caused by the dengue virus, a flavivirus that uses mosquitos Aedes sp. as vect...
| Publicado en: | BioMed Research International Vol. 2014; pp. 825039 - 825040 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
Wiley-Blackwell
2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109680370&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109680370 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 2014 vid: 2014 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 109680370 NLM25157370 2012751896 10.1155/2014/825039 NLM25157370 PMC4135166 109680370 ppf: 825039 ppct: 1 formats: fmt: @attributes: type: P tig: atl: Progress in the identification of dengue virus entry/fusion inhibitors. aug: au: De La Guardia, Carolina Lleonart, Ricardo sug: ab: Dengue fever, a reemerging disease, is putting nearly 2.5 billion people at risk worldwide. The number of infections and the geographic extension of dengue fever infection have increased in the past decade. The disease is caused by the dengue virus, a flavivirus that uses mosquitos Aedes sp. as vectors. The disease has several clinical manifestations, from the mild cold-like illness to the more serious hemorrhagic dengue fever and dengue shock syndrome. Currently, there is no approved drug for the treatment of dengue disease or an effective vaccine to fight the virus. Therefore, the search for antivirals against dengue virus is an active field of research. As new possible receptors and biological pathways of the virus biology are discovered, new strategies are being undertaken to identify possible antiviral molecules. Several groups of researchers have targeted the initial step in the infection as a potential approach to interfere with the virus. The viral entry process is mediated by viral proteins and cellular receptor molecules that end up in the endocytosis of the virion, the fusion of both membranes, and the release of viral RNA in the cytoplasm. This review provides an overview of the targets and progress that has been made in the quest for dengue virus entry inhibitors. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|